Treatment of opioid-use disorders

New England Journal of Medicine

Volumn 375, Issue 4, 2016, Pages 357-368

  Schuckit, Marc A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CLONIDINE; CODEINE; DIAMORPHINE; DIAZEPAM; INFUSION FLUID; LOPERAMIDE; METHADONE; MORPHINE; NALOXONE; NALTREXONE; NAPROXEN; ONDANSETRON; OPIATE; PLACEBO; PROCHLORPERAZINE; TEMAZEPAM; TIZANIDINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT;

ACCIDENTAL DEATH; ANXIETY DISORDER; ARTHRALGIA; BONE PAIN; CAUSE OF DEATH; DETOXIFICATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DRUG INTOXICATION; HUMAN; INSOMNIA; LIFE EVENT; MAINTENANCE THERAPY; MYALGIA; NAUSEA AND VOMITING; OPIATE ADDICTION; OPIOID USE DISORDER; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION CARE; REVIEW; SUBSTANCE ABUSE; UNITED STATES; WITHDRAWAL SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

ADRENERGIC ALPHA-AGONISTS; BUPRENORPHINE; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84979887646     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1604339     Document Type: Review

References (67)

1. O'Brien CP. Drug addiction. In: Brun-ton L, Chabner B, Knollman B, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011:649-66.
2. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014; 8: 153-63.
3. Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015:7-12 (http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf).
4. Brady KT, McCauley JL, Back SE. Prescription opioid misuse, abuse, and treatment in the United States: an update. Am J Psychiatry 2016;173:18-26.
5. Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015;372:241-8.
6. Soyka M. New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil 2015; 6: 1-14.
7. Degenhardt L, Whiteford H, Hall WD. The Global Burden of Disease projects: what have we learned about illicit drug use and dependence and their contribution to the global burden of disease? Drug Alcohol Rev 2014;33:4-12.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Publishing, 2013:541-60.
9. Darke S, Marel C, Slade T, Ross J, Mills KL, Teesson M. Patterns and correlates of sustained heroin abstinence: findings from the 11-year follow-up of the Australian Treatment Outcome Study. J Stud Alcohol Drugs 2015; 76: 909-15.
10. Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014;109:79-87.
11. Degenhardt L, Larney S, Kimber J, Farrell M, Hall W. Excess mortality among opioid-using patients treated with oral naltrexone in Australia. Drug Alcohol Rev 2015;34:90-6.
12. Evans E, Li L, Min J, et al. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction 2015; 110:996-1005.
13. Teesson M, Marel C, Darke S, et al. Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study. Addiction 2015;110:986-93.
14. HIV infection and HIV-associated behaviors among injecting drug users - 20 cities, United States, 2009. MMWR Morb Mortal Wkly Rep 2012; 61: 133-8.
15. Degenhardt L, Larney S, Kimber J, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction 2014;109:1306-17.
16. Park T W, Cheng DM, Lloyd-Travaglini CA, Bernstein J, Palfai TP, Saitz R. Changes in health outcomes as a function of abstinence and reduction in illicit psychoactive drug use: a prospective study in primary care. Addiction 2015; 110:1476-83.
17. Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse 2012; 3 8:187-99.
18. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psycho-active Drugs 2003;35:253-9.
19. O'Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA 2005; 294: 961-3.
20. Sullivan LE, Fiellin DA. Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med 2008;148:662-70.
21. Kowalczyk WJ, Phillips KA, Jobes ML, et al. Clonidine maintenance prolongs opioid abstinence and decouples stress from craving in daily life: a randomized controlled trial with ecological momentary assessment. Am J Psychiatry 2015; 172:760-7.
22. Gowing L, Farrell MF, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2014; 3: CD002024.
23. Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011:481-525.
24. Amato L, Davoli M, Minozzi S, Ferro-ni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2013;2:CD003409.
25. Wright NMJ, Sheard L, Adams CE, et al. Comparison of methadone and buprenor-phine for opiate detoxification (LEEDS trial): a randomised controlled trial. Br J Gen Pract 2011;61(593):e772-80.
26. Senay EC, Dorus W, Goldberg F, Thornton W. Withdrawal from metha-done maintenance: rate of withdrawal and expectation. Arch Gen Psychiatry 1977; 34: 361-7.
27. Whiteside GT, Kyle DJ. A review of the NOP (ORL-1)-nociceptin/orphanin FQ system covering receptor structure, distribution, role in analgesia and reward and interactions with other receptors. In: Ko M-C, Husbands SM, eds. Research and development of opioid-related ligands. Washington, DC: American Chemical Society, 2013:326-68.
28. Heit HA, Gourlay DL. Buprenorphine: new tricks with an old molecule for pain management. Clin J Pain 2008; 24: 93-7.
29. Chavkin C. The therapeutic potential of κ-opioids for treatment of pain and addiction. Neuropsychopharmacology 2011; 36:369-70.
30. Schuckit MA. Alcohol-use disorders. Lancet 2009;373:492-501.
31. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008;165:179-87.
32. Vasilaki EI, Hosier SG, Cox WM. The efficacy of motivational interviewing as a brief intervention for excessive drinking: a meta-analytic review. Alcohol Alcohol 2006;41:328-35.
33. Humphreys K, Blodgett JC, Wagner TH. Estimating the efficacy of Alcoholics Anonymous without self-selection bias: an instrumental variables re-analysis of randomized clinical trials. Alcohol Clin Exp Res 2014;38:2688-94.
34. Lee JD, McDonald R, Grossman E, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction 2015; 110: 1008-14.
35. Lapham SC, McMillan GP. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders. J Addict Med 2011; 5: 163-9.
36. Krupitsky EM, Zvartau EE, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry 2012;69:973-81.
37. Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs 2012;73:991-7.
38. Sigmon SC, Dunn KE, Saulsgiver K, et al. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 2013;70:1347-54.
39. Hulse GK, Ngo HTT, Tait RJ. Risk factors for craving and relapse in heroin users treated with oral or implant naltrex-one. Biol Psychiatry 2010; 68: 296-302.
40. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 2006; 101: 491-503.
41. Nosyk B, Li L, Evans E, et al. Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012. Drug Alcohol Depend 2014;143:149-57.
42. Friedmann PD, Schwartz RP. Just call it "treatment." Addict Sci Clin Pract 2012; 7: 10 .
43. Johnson B, Richert T. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors. Int J Drug Policy 2015; 26: 183-90.
44. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and bu-prenorphine treatment. Drug Alcohol Depend 2009;104:73-7.
45. Leece P, Cavacuiti C, Macdonald EM, et al. Predictors of opioid-related death during methadone therapy. J Subst Abuse Treat 2015;57:30-5.
46. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Ann Intern Med 2009;150:387-95.
47. Methadone maintenance treatment program standards and clinical guidelines. 4th ed. Toronto: College of Physicians and Surgeons of Ontario, 2011.
48. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; 3: CD002208.
49. Pollack HA, D'Aunno T. Dosage patterns in methadone treatment: results from a national survey, 1988-2005. Health Serv Res 2008;43:2143-63.
50. D'Aunno T, Pollack HA, Frimpong JA, Wuchiett D. Evidence-based treatment for opioid disorders: a 23-year national study of methadone dose levels. J Subst Abuse Treat 2014;47:245-50.
51. Federal guidelines for opioid treatment programs. Rockville, MD: Substance Abuse and Mental Health Services Administration, March 2015 (http://store .samhsa .gov/shin/content/PEP15-FEDGUIDEOTP/ PEP15-FEDGUIDEOTP.pdf).
52. Cousins G, Boland F, Courtney B, Barry J, Lyons S, Fahey T. Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study. Addiction 2016; 111: 73-82.
53. Huang CL, Lee CW. Factors associated with mortality among heroin users after seeking treatment with methadone: a population-based cohort study in Taiwan. J Subst Abuse Treat 2013; 44: 295-300.
54. Pierce M, Bird SM, Hickman M, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction 2016;111:298-308.
55. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011;8:CD004145.
56. Buprenorphine Initiative in the VA (BIV). Buprenorphine resource guide. Washington, DC: Department of Veterans Affairs, June 2009 (http://www .mental health.va.gov/providers/sud/docs/VA-Bup-Resource-Guidev9-1.pdf).
57. Clinical guidelines for the use of bu-prenorphine in the treatment of opioid addiction: a treatment improvement protocol. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004 (http://buprenorphine .samhsa .gov/Bup-Guidelines.pdf).
58. Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of bu-prenorphine sublingual tablets and film. J Subst Abuse Treat 2014; 47: 27-34.
59. Launonen E, Alho H, Kotovirta E, Wallace I, Simojoki K. Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients. Int J Drug Policy 2015;26:875-82.
60. Lintzeris N, Leung SY, Dunlop AJ, et al. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug Alcohol Depend 2013; 131:119-26.
61. Nielsen S, Hillhouse M, Mooney L, Ang A, Ling W. Buprenorphine pharma-cotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users. J Subst Abuse Treat 2015; 48: 70-6.
62. Fareed A, Vayalapalli S, Casarella J, Amar R, Drexler K. Heroin anticraving medications: a systematic review. Am J Drug Alcohol Abuse 2010; 36: 332-41.
63. Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat 2015; 52: 48-57.
64. D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA 2015;313:1636-44.
65. Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat 2010; 39: 340-52.
66. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;2:CD002207.
67. Potter JS, Marino EN, Hillhouse MP, et al. Buprenorphine/naloxone and meth-adone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs 2013; 74: 605-13.